Aligos Therapeutics. has been granted a patent for compounds of Formula (I) and their pharmaceutically acceptable salts. The patent includes pharmaceutical compositions and methods for synthesizing these compounds, as well as their application in treating various diseases and conditions. GlobalData’s report on Aligos Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aligos Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Aligos Therapeutics's grant share as of July 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12065428B2 outlines a novel compound characterized by a specific chemical structure, referred to as Formula (I), along with its pharmaceutically acceptable salts. The claims detail various structural modifications and substitutions that can be made to the compound, including the presence of cycloalkyl groups, alkyl groups, and heterocyclic components. Notably, the patent specifies that Ring A2 can be an unsubstituted monocyclic C3-6 cycloalkyl, with further claims elaborating on the nature of substituents such as R8a and R8b, which can include alkyl and haloalkyl groups. The claims also explore various nitrogen-containing heterocycles that can be incorporated into the compound's structure.
In addition to the compound itself, the patent describes pharmaceutical compositions that include the compound and methods for treating coronavirus infections. Specifically, it outlines a method for administering the compound to subjects in need, potentially in conjunction with other therapeutic agents such as ACE inhibitors, anticoagulants, and various antiviral medications. Furthermore, the patent claims a method for inhibiting coronavirus protease activity, emphasizing the compound's selective inhibition of the coronavirus protease compared to Cathepsin L. Overall, the patent presents a comprehensive framework for the development of therapeutic agents targeting coronavirus infections, leveraging the unique structural properties of the claimed compound.
To know more about GlobalData’s detailed insights on Aligos Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
